Press Releases

PHILADELPHIA, Nov. 11, 2009 (GLOBE NEWSWIRE) -- Law Offices Bernard M. Gross, P.C. commenced a class action lawsuit in the United States District Court, Eastern District of Pennsylvania, 09cv5262, on behalf of purchasers of the securities of Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company")(AMEX: HEB) between February 18, 2009 and October 30, 2009, inclusive (the "Class Period"), seeking to pursue remedies under the Securities Exchange Act of 1934. The action is pending before the Honorable Paul Diamond. If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from November 10, 2009. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff's counsel, Deborah R. Gross or Susan R. Gross at 866-561-3600 or 215-561-3600 or via email at debbie@bernardmgross.com or susang@bernardmgross.com. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of its choice, or may choose to do nothing and remain an absent class member. A copy of the complaint is available from the Court or can be viewed on the Law Offices Bernard M. Gross, P.C. website at www.bernardmgross.com.

Hemispherx is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based chronic disorders. The Company's products include Ampligen, an experimental drug undergoing clinical development for the treatment of chronic fatigue syndrome.

The Complaint alleges that during the Class Period, defendants misled investors regarding the status of Hemispherx's New Drug Application ("NDA") for Ampligen with the U.S. Food and Drug Administration ("FDA"). Specifically, defendants failed to disclose that the FDA had requested several reports from the Company before the NDA could even be considered, thus delaying the possible approval of Ampligen by several months at a minimum. Then, on November 2, 2009, when the Company belatedly disclosed this information, the price of Hemispherx's securities dropped from $1.45 on the previous trading day to close at $1.13 on November 3, 2009, a drop of more than 20%.

Plaintiff seeks to recover damages on behalf of all persons who purchased the securities of Hemispherx Biopharma, Inc. between February 18, 2009 and October 30, 2009, inclusive. The plaintiff is represented by Law Offices Bernard M. Gross P.C. The firm has expertise in prosecuting investor class actions and extensive experience in actions involving financial fraud.

If you wish to discuss this action or have any questions concerning this Notice or rights or interests with respect to these matters,

 PLEASE CONTACT:  Law Offices Bernard M. Gross, P.C.
                  Susan R. Gross, Esq.
                  Deborah R. Gross, Esq.
                  Telephone: 866-561-3600 (toll free) or 215-561-3600
         E-mail:  susang@bernardmgross.com or
                  debbie@bernardmgross.com.
                  Website: http://www.bernardmgross.com

CONTACT:  Law Offices Bernard M. Gross, P.C.
          866-561-3600

DENVER, Nov. 11 /PRNewswire/ -- Forensic Technology Inc. is proud to be associated with this year's winners of the prestigious 2009 August Vollmer Excellence in Forensic Science Award. Presented during the International Association of Chiefs of Police (IACP) conference last month in Denver, Colorado, the August Vollmer Award recognizes the innovative use of forensic technology by law enforcement.

Rocky Edwards and Louis Martinez of the Santa Ana Police Department won the award for Innovation in Forensic Technology. Their diligent work on a cold case dating from 1994 relied heavily on Forensic Technology's IBIS® BULLETTRAX-3D(TM) system, a new ballistics identification technology.

"Our technology has been used to help solve crimes in nearly 50 countries since 1992. To see our new IBIS® TRAX-3D(TM) system play such a significant a role in this cold case reinforces our core belief that our systems can truly help make our society a safer place," said Robert Walsh, President of Forensic Technology.

For over 13 years, Californian detectives were unable to link the suspected murder weapon to the fatal bullet. Edwards traveled to Forensic Technology headquarters in Montreal, Canada, and, using the BULLETTRAX-3D system, he imaged the autopsy bullet. He was then able to confirm the link and identify the murder weapon. When presented with the evidence, the accused pleaded guilty and is currently serving 35 years for murder.

A second August Vollmer Award was presented for Significant Investigative Value in a Major Crime to the Houston Crime Laboratory Division for their diligent efforts in linking 12 different investigations involving members of the La Tercera Crips (LTC) gang over a 10-month period. Using IBIS, the NIBIN network, and an aggressive approach to ballistic identification, the Houston Crime Laboratory was able to quickly relay information back to detectives that resulted in the arrest of eight gang members and the recovery of some of the murder weapons.

About the NIBIN Network:

The National Integrated Ballistic Information Network (NIBIN) network in the United States connects over 200 agencies and allows investigators to link crimes, guns, and suspects across jurisdictions and state lines. Powered by IBIS technology, NIBIN contains over 1.5 million pieces of evidence, and has helped law enforcement link more than 30,000 crimes.

On October 2, 2009, at the Major City Chiefs Meeting in Denver, Colorado, Acting Director Kenneth Melson of the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) announced that the NIBIN program was a "personal priority".

About the August Vollmer Awards

IACP recognizes the significant impact that forensic science has on the criminal justice system. The August Vollmer Excellence in Forensic Science Award has been created to honor the proactive, innovative use of forensic technologies by law enforcement. Presented yearly at the IACP conference, awards are given in five categories.

About Forensic Technology

Forensic Technology pioneered automated ballistics identification more than 15 years ago and continues to be a leader in ballistics and firearm identification technologies that promote a safer society. We partner with hundreds of public safety agencies in over 45 countries and territories, providing cost-effective and sustainable solutions. With vast experience in scalable-networked solutions, we employ a dedicated team of engineering, forensic, and law enforcement professionals around the world.

IBIS technology can find the "needle in the haystack", suggesting possible matches between pairs of spent bullets and cartridge cases at speeds well beyond human capacity, in order to help forensic experts give detectives more timely information about crimes, guns, and suspects.

For more information about Forensic Technology please visit: www.forensictechnology.com

CONTACT: Andre Demers, T: +1-514-485-5610, C: +1-514-777-8616, press@contactft.com

SOURCE Forensic Technology Inc.

SALT LAKE CITY--(BUSINESS WIRE)-- Garb-Oil & Power Corporation (OTCBB: GARB) www.garbop.com announces the company's "Green-Earth Initiative" for 2010. The driving objective behind Garb's initiative is the strategic vision of creating a "NoWasteTM" environment by providing profitable solutions and technology to the recycling and energy industries, in line with the company's strategic 5-year outlook recently presented and our ClosedCycle(TM) principal.

Garb's Green-Earth Initiative comprises three directives:

  1. To provide the recycling industry with cutting-edge machines and equipment
     to improve the efficiency, profitability and options in Garb's rubber
     recycling shredders, rubber knife mills, rubber secondary shredders, rubber
     granulators and to improve the global industry as a whole by proving
     E-scrap shredders and E-scrap Granulators.
  2. To build progressive rubber recycling plants and E-scrap recycling plants
     using the latest industry technology, Garb patents, and Garb know-how and
     trade secrets to effectively and efficiently convert the worldwide waste
     problem into a value-added and environmentally-sound resource goldmine.
  3. To be at the forefront of research and development in the processing and
     refining of waste rubber products, waste E-scrap products and to develop
     new profitable applications for processed recycled goods in order to create
     new, economically viable, end-use products according to the NoWasteTM
     objective.

Garb's Green-Earth Initiative is on schedule to be in full force starting February 1, 2010. Garb recently announced (Read the full news release) the company's new line of state-of-the-art rubber shredders and rubber granulators, waste shredders and waste granulators, which Garb views as critical preparatory components needed for the launch of its initiative and crucial to the initiative's future success. Over the next several months Garb will release announcements as further critical benchmarks are accomplished while the company prepares for the official launch of its Green-Earth Initiative in February. For up-to-date information on Garb's progress please email info@garbmail.com and put "Mailing List" in the subject line.

About Garb-Oil & Power Corporation

Garb is a company dedicated to the production and sale of machinery for the processing of a wide range of waste categories with a specialization in waste rubber. Garb possesses a unique technology for processing OTR tires. Garb designs and constructs plants for processing waste on a turnkey basis. Garb specializes in refining waste rubber from tires of all types and technical rubber products. The types and grades of crumb rubber produced from Garb plants are the most desirable and best recycled rubber for manufacturing rubber products.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained in this document that are not historical fact, are forward-looking statements based upon management's current expectations. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. The results anticipated by any or all of these forward-looking statements may not occur. Garb-Oil & Power Corporation is not required to update its forward-looking statements.

    Source: Garb-Oil & Power Corporation

CHICAGO, IL -- (MARKET WIRE) -- 11/11/09 -- Lights, camera, action! Or in this case: Writers, designers, publish!

HealthyLifeNetwork.com is officially online and making its healthful presence known on the world-wide web. The new site has been in development for sometime but overall the time to market from concept to publish was fast-tracked by a Chicago-based team of writers, editors, designers and marketing wizards.

Topics covered on HealthyLifeNetwork.com include physical fitness, diet, healthy eating and healthy recipes, sexual health, family, finance, home & garden, tech as well as travel. Additional topics and tabs included to nicely round out the site include automotive, education, entertainment, jobs, politics and weather.

"Reviewing the online portals and publications which cater to the healthy life enthusiasts available prior to this point revealed to us a need. There simply wasn't enough useful and up to the minute information out there for those interested in health topics," said Eric Wood, Healthy Life Network's marketing director. "With Healthy Life Network now online we aim to give the large segment of consumers who are interested in the healthy lifestyle and its issues a fresh, hip perspective on the latest ideas and news in living the healthy life."

Living the healthy life involves more than just sticking with the things a person has heard their whole lives: "Eat your vegetables. Get enough sleep. An apple a day." etc., etc.

Consumers interested in living the healthy life and reaping its benefits need positive reinforcement but they also need health information that is current, such as the latest developments on the H1N1 Swine Flu virus as well as its symptoms and treatment, the latest research & developments in healthy eating and nutrition, as well as the newest and most effective exercise techniques, tools and routines to improve and shape the human body to its greatest potential.

Consumers can dive right in to the healthy life at: www.healthylifenetwork.com

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
John Chase
312-609-0080
Email Contact

BERKELEY, Calif., Nov. 11, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of antibody therapeutics, announced that Fred Kurland, Vice President and Chief Financial Officer of XOMA, is scheduled to present at the 6th annual Lazard Healthcare Conference on Wednesday, November 18, at 1:45 pm. Eastern time in New York City.

The presentation will be webcast live at http://www.wsw.com/webcast/lz6/xoma/ or via the Investors tab at the XOMA website, www.xoma.com. An archived version of the webcast will be available for 90 days following the presentation.

About XOMA

XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government. The company's proprietary product pipeline includes:

  * XOMA 052, an anti-IL-1 beta antibody in Phase 2 development for
    diabetes and cardiovascular disease, with potential for the
    treatment of a wide range of inflammatory diseases
  * XOMA 3AB, an antibody candidate in pre-IND studies to neutralize
    the botulinum toxin, among the most deadly potential bioterror
    threats, under development through funding provided by the
    National Institutes of Allergy and Infectious Diseases of the
    National Institutes of Health
  * A preclinical pipeline with candidates in development for
    inflammatory, cardiometabolic, infectious and oncologic diseases.

In addition to its proprietary pipeline, XOMA develops products with premier pharmaceutical companies including Novartis AG, Merck & Co., Inc. and Takeda Pharmaceutical Company Limited.

XOMA has multiple revenue streams resulting from the licensing of its antibody technologies, product royalties, development collaborations and biodefense contracts. XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease.

The company has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary Human Engineering(TM), affinity maturation, Bacterial Cell Expression (BCE) and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, more than 50 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are in clinical development.

XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of about 200 employees at its Berkeley, California location. For more information, please visit http://www.xoma.com.

The XOMA Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960

Forward-Looking Statements

Certain statements contained herein concerning product development and capabilities of XOMA's technologies or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market.

These risks, including those related to inability to comply with NASDAQ's continued listing requirements; the declining and generally unstable nature of current economic conditions; the results of discovery research and pre-clinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); changes in the status of existing collaborative and licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations; XOMA's ability to meet the demands of the United States government agency with which it has entered into its government contracts; competition; market demands for products; scale-up and marketing capabilities; availability of additional licensing or collaboration opportunities; international operations; share price volatility; XOMA's financing needs and opportunities; uncertainties regarding the status of biotechnology patents; uncertainties as to the costs of protecting intellectual property; and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects.

CONTACT:  XOMA Ltd.
          Company and Investor Contact:
          Carol DeGuzman
          510-204-7270
          deguzman@xoma.com

          Porter Novelli Life Sciences
          Media Contact:
          Carolyn Hawley
          619-849-5375
          chawley@pnlifesciences.com